Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flucortac for neurogenic orthostatic hypotension
2018-003905-25Phase 4Active
- Sponsor
- HAC Pharma
- Start
- Jan 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of fludrocortisone in Neurogenic Orthostatic Hypotension (nOH) and orthostatic hypotension (OH), sponsored by HAC Pharma. Primary endpoints: Change in systolic blood pressure after 5 minutes of active standing, Change in diastolic blood pressure after 5 minutes of active standing and 1 more. Started Jan 2019; status: active.
02
Drugs
fludrocortisone
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)orthostatic hypotension (OH)
Beyond the preview
Go deeper on 2018-003905-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003905-25.